Compare Hilton Hotels Corporation Common Stock (HLT) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Viatris Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $320.44 (market cap $70.82B), while Viatris Inc trades at $16.23 (market cap $18.69B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 3.8× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| HLT | VTRS | |
|---|---|---|
Market Cap | $70.82B | $18.69B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $17.86 |
52-Week Low | $256.75 | $9.49 |
Enterprise Value | $83.83B | $30.80B |
Dividend Yield | 0.19% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide Holdings (HLT) trades at $311.00, down 2.08% over 24 hours, amid a bearish technical signal. The stock shows strong fundamentals with Q2 2026 EPS of $2.29 meeting estimates and revenue growth to $12.04 billion in 2025. However, a high P/E of 46.21 and rising debt-to-asset ratio to 73.88% in 2025 highlight valuation and leverage concerns. Recent news includes a 50-day strike at a Seattle hotel and mixed institutional trading activity.
The outlook for HLT is cautiously optimistic, supported by robust travel demand and a record pipeline, but tempered by premium valuation and debt risks. Analysts maintain a buy consensus with a $352.00 price target, suggesting 13% upside. Key risks include labor disputes, soft international demand, and interest rate sensitivity. Investors should weigh growth prospects against financial leverage and market sentiment shifts.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
